`Case 1:15-cv-00116-LPS Document 162 Filed 07/25/16 Page 1 of 7 PagelD #: 4038
`
`PTRABEMARK.
`
`Mall Sten 8
`Director of the U.S. Patent sad Trademark Office
`P.O. Box 1480
`Alexandria, VA 223E-1450
`
`REPORT ON THE
`FILING QR DETERMINATION OF AN
`ACTION REGARDINGA PATENT OR
`
`ia Compliance wih:SUS. § B80 andlor ELS. § PLN you arehereby advised (hat. w court action has boon
`filed ig the US. CNeadet
`for the District of Delaware
`
`
`EY Trademarks os
`POCAET NG,
`15.476 (LPS)
`
`SSeS
`22S
`|
`
`i
`TTRaR ee
`Lor the Distiel ot Betawaré
`
`DEFENDANT
`
`PAR PHARMACEUTICAL INC.
`
`ROLDEROF PATENT OR TRADEMARK
`Cosma Tachnologigs Linkted
`Dismissed fram Action by First Amended Complaint ta6/204 §
`Cosmo Technologies Limited
`
`an the ilownig
`H2E2015
`
`
`SPORE £
`
`CHAOEREEREWD
`
`yy
`
`ATS
`
`‘
`BPPZIZ008
`qOFF2508
`
`Je
`
`Steg,
`
`geet
`
`“pe
`
`95%
`
`3,
`
`PUAEQ0T4
`
`Cosme Technolagies Limited
`Dismisesd fram Action by First Amended Complaint FANG §
`
`Sa
`iv the abowe-—cniitied cane, te folowing pateniis¥ fadamariys) have been inched:
`PINCLUDED BY
`
`af Agwendetit
`DATE OP PATENT
`CHE TRADEMARS
`
`inthe abass-sentitiad cass, the folowing decision has been rendered oF hicigemant dssasd:
`DECMONGUDBEMERT
`
`Carent Judgment Bkgh Vrtom isgad
`
`CopyUpon initiation of ection, mailthis capy to Director Copy d—~Upan termination af action, mail this copy iy Director
`Copy 2Upon Gling document adding patent(s} mall this copy io Dirextor Cony 4--Clase fle copy
`
`Eee 2018 |
`
`

`

`Case 1:15-cv-00116-LPS Document 162 Filed 07/25/16 Page 2 of 7 PagelD #: 4039
`
`
`
`
`
`COSMO TECHNOLOGIES LIMITED, af al.
`
`PAR PHARMACEUTICAL, ING.
`
`
`
`snnenntnnenmnnnnimnrnnnnnnannapacnnsnannacnannnnnennnnnt
`
`
`PATENTOR
`DATE OF PATENT
`
`HOLDER OF PATENT OR TRADEMARK
`TRADEMARK NO.
`OR TRADEMARK
`
`Cosmo Technologies Limited
`TUS2042
`
`
`
`
`
`DATE FILED
`US. DISTRICT COURT
`
`
`
`ROCKET NO.
`
`2f2i2015
`for the District of Delaware
`
`15-716 (LPS)
`
`DEFENDANT
`PLAINTIFF
`
`
`
`
`

`

`Case 1:15-cv-00116-LPS Document 162 Filed 07/25/16 Page 3 of 7 PagelD #: 4040
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`COSMO TECHNOLOGIES LIMITED,
`VALEANT PHARMACEUTICALS
`LUXEMBOURG 8.A. RBLL., and
`SANTARUS,INC.,
`
`Plaintiffs,
`
`vv,
`
`PAR PHARMACEUTICAL, INC.,
`
`Defendant.
`
`
`
`
`
`
`
`
`
`
`
`Civil Action No. 1:15-cv-00116-LPS
`
`
`
`
`
`
`
`
`
`
`
`SmeeSane!Nae!“ane!Sane!“ane!“ann!“ann!“mee!“Sage“Sage“neenee’
`
`Plaintiffs Cosmo Technologies Limited (“Cosmo”}, Valeant Pharmaceuticals
`Luxembourg Sard. CValeant’}, Santarus, Inc. (‘Santarus”) (collectively, “Plaintiffs”)} and
`
`Detendant Par Pharmaceutical, Inc. (hereinafter “Par” and, together with Plaintiffs, ““Parties’”)
`
`have agreed to terms and conditions representing a negotiated settlement of this action and have
`
`set forth those terms and conditions in a Settlement and License Agreement by and between the
`
`Parties.
`
`Accordingly, the Parties, by their respective undersigned attorneys, herebystipulate and
`
`consent to the entry of a judgment and an mypunction in and dismissal of this action pursuant to
`
`Rule 41(a}(2) of the Federal Rules of Civil Procedure, as follows:
`
`The CourtHEREBY ORDERS, ADJUDGES AND DECREES:
`
`1,
`
`This Court has jurisdiction over the subject matter of this action and personal
`
`yurisdiction over the Parties.
`
`

`

`Case 1:15-cv-00116-LPS Document 162 Filed 07/25/16 Page 4 of 7 PagelD #: 4041
`
`2.
`
`The term “Affiliate” means: any Person that controls, is controlled by or is under
`
`common control with such first Person. For purposes of this definition only, “control” means (1)
`
`to possess, directly or indirectly, the power to direct managementorpolicies of a Person,
`
`whether through ownership of votimg securities, by contract relating to voting rights or corporate
`
`governance, or otherwise or (2) to own, directly or indirectly, more than fifty percent (50%) of
`
`the outstanding voting securities, or other voting ownership interest, of a Person.
`
`3.
`
`The term “NDA Approved Product” means the product that is approved for
`
`distribution in the United States under New Drug Application No. 203634.
`
`4.
`
`The term “Par’s ANDA” means AbbreviatedNow Drag Application No, 266131,
`
`including all amendments and supplements thereto.
`
`5.
`
`The term “Par’s ANDA Product” means budesonide tablets that are the subject of
`
`Par’s ANDA.
`
`6.
`
`The term “Person” means an individual, sole proprietorship, partnership, limited
`
`partnership, limited liability partnership, corporation, limited hability company, business trast,
`
`joint stock company, trust, incorporated association, joint venture or sumilar entityor
`
`organization, including a government or political subdivision, department or agency of a
`
`government,
`
`7.
`
`The term “Proceeding” means anyaction, litigation or other proceeding
`
`(including any interference, re-examination, infer partes review, post-grant, ex parte, or
`
`opposition proceeding) at or before the USPTOor any court or other governmental body.
`
`&,
`
`The term “USPTO” means the United States Patent and Trademark Office and
`
`shall include the Patent Trial and Appeal Board, the Board of Patent Appeals and Interferences,
`
`and any other admmistrative board or court related thereto.
`
`

`

`Case 1:15-cv-00116-LPS Document 162 Filed 07/25/16 Page 5 of 7 PagelD #: 4042 |
`
`9.
`
`Par, its Affiliates and each of their respective predecessors, successors, assigns,
`
`agents, officers, directors, employees, and representatives (collectively “Par’s Releasors”) have
`
`acknowledged, admitted, and agreed that each of US. Patent No. 7,416,651; U.S. Patent No.
`
`7,431,943; US. Patent No. 8,293,273: US. Patent No. 8,784,888: US. Patent No. 8,895,064;
`
`ULS. Patent No. RE 43,799; US. Patent No. 9,192,581; and U.S. Patent No. 9,320,716 (each
`
`hereinafter “Asserted Patent}, is valid and enforceable in the above-captioned litigation or any
`
`other or fature Proceeding the subject matter of which is Par’s ANDA Product.
`
`10.
`
`Each of Par’s Releasors has acknowledged, admitted, and agreed that each
`
`Asserted and Related Patent would be infrmeed by the making, having made, use, sale, offer to
`
`sell, or importation of Par’s ANDA Product in or for the United States.
`
`Li.
`
`Each of Par’s Releasors has agreed not to challenge or otherwise dispute or
`
`contest, and not to assist any other Person, whether directly or indirectly, m challenging or
`
`otherwise disputing or contesting, the validity, enforceability or patentability of anyof the
`
`Asserted Patents in any Proceeding, as such assertions relate to Par’s ANDA or Par’sANDA
`
`Product; or the infringement of any of the Asserted Patents by the making, having made, use,
`
`sale, offer to sell, or importation of Par’s ANDA Product in or for the United States.
`
`12.
`
`Par, inchiding its successors and assigns, are enjoined, directly and indirectly, on
`
`their own part or through their respective Affiliates, licensees, sublicensees or other Persons,
`
`from (a) marketing, distributing, having distributed, offering for sale, selling or taking orders for
`
`Pars ANDA Product in or for the United States or (b) icensing, sublicensing, enabling,
`
`permitting or causing (or continuing to license, sublicense, knowingly enable, permit or cause}
`
`any Person to do any of the foregoing, except in each case (a} and (b) solelyas andto the extent
`
`specifically authorized by the Settlement and License Agreement.
`
`

`

`» Case 1:15-cv-00116-LPS Document 162 Filed 07/25/16 Page 6 of 7 PagelD #: 4043
`
`~
`13.
`
`In the event of breach or violation of the terms of this Consent Judgment and
`
`Dismissal, jurisdiction and venue for an action for preliminary and permanent mjunctions against
`
`the breaching conduct exists in this Court, and the Parties hereby waive anyand all defenses
`
`based on subject matter yuarisdiction, personal jurisdiction and mconvenient or improper forum or
`
`venue.
`
`i4.
`
`is.
`
`All claims and counterclaims im this action are dismissed with prejudice.
`
`‘This Consent Judgment and Dismissal affects a settlement between the Parties of
`
`thei claims and counterclaims in the present action.
`
`It does not constitute a judgment on the
`
`mierits in respect of any such claim or counterclaim.
`
`16.
`
`Except as otherwise provided by the Settlement and License Agreement, cach
`
`Party shall bear its own costs and attorneys’ fees in respect of this action.
`
`i7.
`
` Complance with this Consent Judgment and Eismissal may be enforced by the
`
`Parties and their respective successors and permitted assigns.
`
`18.
`
`This Court retains jurisdiction to enforce or supervise performance underthis
`
`Consent Judgment and Dismussal of the aforesaid Settlement and License Agreement.
`
`[Signatures appear on next page.|
`
`

`

`» Case 1:15-cv-00116-LPS Document 162 Filed 07/25/16 Page 7 of 7 PagelD #: 4044.
`
`eo.
`SO ORDERED this “3 day of “4
`
` The Honorable Leonard P. Stari
`
`United States District Court Judge
`
`Morris, NICHOLS, ARSHT & TUNNELL LLP
`
`YOUNG CONAWAYSTARGAT? & TAYtor LLP
`
`/3f Maryellen Noreika
`
`Jack B. Bhimenfeld Gi014)
`Maryellen Noreika 3203}
`i201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899-1347
`{302} 658-9266
`fohumenfeld@mnat.com
`mnoreika@mmai.com
`
`/i/ Karen £, Pascale
`Karen L. Pascale (#2903)
`James L. Higeims (#5021}
`Rodney Square
`1000 North King Street
`Wilmington, DE 19899-0391
`Telephone: 302-571-6600
`kpascale@ycst.com
`jhiggins@yest.com
`
`Attornevs for Plaintiffs
`
`Attorneys for Par Pharmaceuticals, Inc.
`
`OF COUNSEL:
`
`OF COUNSEL:
`
`Melanie R. Rupert
`Dravid M. Conca
`Nicholas Tymoczko
`Jennifer Nguyen
`Scott Peachman
`PAUL HasTineas LEP
`200 Park Avenue
`NewYork, NY 10166
`(212) 318-6000
`
`Richard J. Berman
`Janine A. Carlan
`TanielBE. Anderson
`Abmed Abdel-Rahman
`ARENT FOX LLP
`i717 & Street, NW
`Washington, DC 20036-3342
`(202) 857-6000
`
`'
`
`Cay
`
`